Cefotil 750 mg/vial (IM/IV Injection)
750 mg vial: ৳ 132.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Cefuroxime axetil |
| Company | Square pharmaceuticals plc |
| Also available as |
Title
- Cefotil Tablets
Categories
- Medicine
- Antibiotics
- Cephalosporins
Description
- Cefuroxime is indicated for the treatment of infections caused by sensitive bacteria, such as Pharyngitis/Tonsillitis, Acute Bacterial Otitis Media, Acute bacterial maxillary sinusitis, Lower respiratory tract infections, Skin and skin-structure infections, Urinary tract infections, Bone and Joint Infections, Gonorrhoea, Early Lyme Disease.
Color Options
- White
Dosage Form
- Tablet
- Suspension
Pharmacology
- Broad-spectrum bactericidal activity against a wide range of common pathogens, including β-lactamase producing strains.
Dosage for Adolescents and Adults
- 250-500 mg b.i.d. for 5-10 days
Dosage for Paediatric Patients
- 20 mg/kg/day b.i.d for 5-10 days
Parenteral Dosage for Adults
- 750 mg three times daily by IM or IV injection
Parenteral Dosage for Children
- 30 - 100 mg/kg/day given in 3 or 4 equally divided doses
Parenteral Dosage for Neonate
- 30 - 100 mg/kg/day given in 2 or 3 equally divided doses
Administration Recommendation
- Use of freshly reconstituted solution is recommended.
Interaction
- No potentially hazardous interactions reported.
Contraindications
- Known allergy to Cephalosporins.
Side Effects
- Rashes, gastrointestinal disturbances, potential overgrowth of non-susceptible organisms.
Pregnancy Category
- Category B
Lactation
- Excreted in human milk, caution advised when administered to a nursing woman.
Precautions
- Care with concurrent treatment with potent diuretics, history of colitis, and hypersensitivity to penicillin.
Therapeutic Class
- Second generation Cephalosporins
Reconstitution
- For 750 mg intramuscular and intravenous injection: Add water for injection and shake gently for dispersion.
Storage Conditions
- Store in a cool, dry place below 30<sup>o</sup>C, away from light & moisture.